查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827367

基因組學市場（按產品類型、應用、最終用戶和技術）—2025-2032 年全球預測

Genomics Market by Product Type, Application, End User, Technology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年基因組學市場規模將成長至 1,122.6 億美元，複合年成長率為 10.03%。

主要市場統計數據
基準年2024年 522.2億美元
預計2025年 571.5億美元
預測年份：2032年 1122.6億美元
複合年成長率（%） 10.03%

為研究、臨床和商業相關人員制定當前基因組學趨勢、技術考量和關鍵決策的策略方向

基因組學領域持續快速發展，技術創新、跨部門合作以及不斷變化的監管環境重塑了研究機構、醫療保健提供者和商業公司的策略重點。本簡介概述了高階主管、研發主管和採購團隊在評估技術採用、合作機會和資本配置時必須考慮的關鍵促進因素。此外，本簡介也將該主題置於更廣泛的背景下進行探討，包括轉化科學、供應鏈韌性以及對精準治療和診斷方法日益成長的需求。

新的定序平台、改進的PCR方法以及微陣列設計的創新正在釋放新的實驗能力，同時也改變了供應商的競爭和服務模式。同時，從農業到個人化醫療等各種應用領域，組織必須管理的端點數量和資料類型也不斷增加。因此，技術投資或外包的決策不僅取決於儀器性能和試劑質量，還取決於與生物資訊流程的整合、試樣處理通量的可擴展性以及耗材的長期可用性。

在此背景下，相關人員必須權衡短期營運需求與長期策略目標。本報告的第一部分探討了許多關鍵問題，例如，面對多樣化的用例，如何確定平台選擇的優先級，如何降低供應和監管風險，以及如何將技術優勢轉化為可衡量的臨床和商業性價值。本書旨在幫助讀者掌握對研究、臨床和商業成果產生最大影響的槓桿。

技術突破、商業模式演變以及監管預期的提高如何改變基因組學領域的競爭動態和業務重點

成熟的技術、不斷變化的經營模式以及新興的政策動態相互作用，正在改變基因組學格局，並引發需要策略調整的重大變革。高通量定序和單細胞技術的進步正在降低產生複雜資料集的門檻，從而促進從孤立實驗向整合多組體學項目的轉變。這種轉變有利於那些能夠將分析深度與強大的資料管理和解讀框架結合的組織，從而不僅透過原始通量，更透過切實可行的洞察脫穎而出。

同時，某些硬體組件的商品化以及以試劑為中心的經營模式的興起正在改變供應商的經濟狀況，並加速規模至上的細分市場的整合。服務供應商正在擴展其端到端解決方案，包括樣本物流、定序、資料處理和法規支持，以吸引那些追求簡單性和品質保證的客戶。同時，人們對精密農業和感染疾病監測的興趣日益濃厚，這正在擴大最終用戶的覆蓋範圍，並催生出能夠快速部署基因組學能力的鄰近市場。

最後，倫理和監管部門對資料隱私、跨國樣本流動和臨床檢驗的關注，已將管治提升到競爭層面。積極整合合規性、透明的資料管理和檢驗的工作流程的組織將佔據有利地位，從而獲得長期價值。這些變革性轉變並非孤立運作，而是動態互動的，這意味著技術選擇、商業性夥伴關係和合規策略必須協調一致，才能有效應對新的情況。

評估2025年關稅如何重塑基因組學業務的籌資策略、供應鏈彈性計畫和供應商風險分配

關稅和貿易限制等措施的實施可能會對基因組學生態系統產生多層次的影響，影響供應商關係、採購決策以及實驗室運作的成本結構。 2025年的關稅促使採購團隊重新評估其供應商組合，實現採購多元化，並加快對替代供應商的資格審查，以確保關鍵設備和耗材的持續供應。這項轉變導致企業更加重視擁有彈性製造足跡和透明關稅減免策略的供應商。

在實踐中，各機構已做出應對，將部分採購轉向國產零件，並增加常用試劑和耗材的戰略存量基準。與服務提供者和設備供應商的合約條款已重新協商，以考慮更長的前置作業時間並分攤跨境物流相關風險。此外，關稅帶來的成本壓力影響了資本支出計劃，一些買家推遲了非必要的設備升級，同時優先採購正在進行的研究和臨床工作流程所需的耗材。

從策略角度來看，關稅凸顯了供應鏈情報和情境規劃的重要性。相關人員正在投資更深入的供應商審核、雙重採購策略，並與製造商建立更緊密的合作，以繪製生產能力圖並識別瓶頸。從中期來看，這些調整可能會鼓勵本地化製造和長期合約安排的擴張，從而即使在貿易政策波動的情況下也能提供可見性和可預測性。因此，雖然關稅帶來了直接挑戰，但它們也加速了整個基因組學領域採購慣例和供應鏈設計的結構性變革。

全面的細分分析涵蓋產品、應用、最終用戶和技術維度，以指導有針對性的研發、商業化和服務策略

了解市場區隔對於制定基因組學領域的產品開發、商業策略和服務交付模式至關重要。市場分析涵蓋產品類型，涵蓋微陣列、PCR、試劑和耗材、定序服務和定序系統。微陣列分為基因表現陣列和SNP基因型鑒定陣列，PCR分為數位PCR和qPCR，試劑和耗材包括酵素和預混液、文庫製備試劑套件以及探針和引物，定序服務包括新一代定序和桑格定序服務，定序系統包括NGS平台和桑格定序儀。這種以產品為中心的觀點突顯了技術創新的發生地點，以及傳統平台的生命週期壓力可能促使其進行再投資或遷移的領域。

從應用角度來看，市場涵蓋農業、診斷、藥物發現和市場開發以及個人化醫療。由於樣本類型和分析要求不同，農業領域分為動物基因組學和作物基因組學。診斷領域分為癌症基因組學、基因檢測和傳染病檢查，每種檢測都需要不同的檢驗途徑和臨床工作流程。藥物發現和開發專注於生物標記的發現和標靶識別，是一項依賴高通量、可重複輸出的活動。個人化醫療包括伴隨診斷和精準醫療，其中臨床整合和監管協調至關重要。

考慮最終用戶揭示了各種組織的需求和購買行為，從學術和政府機構到商業研究組織、醫院和診所、製藥公司和生物技術公司。這些最終用戶在採購複雜程度、吞吐量要求和營運風險接受度能力方面各不相同。透過技術視角評估市場突顯了陣列技術、DNA定序、PCR技術和RNA定序的影響。陣列技術進一步分為微陣列、基因表現陣列和SNP基因型鑒定陣列；DNA定序分為次世代定序和桑格定序；PCR技術分為數位PCR和qPCR；RNA定序分為批量RNA定序和定序細胞RNA定序。 PCR技術也分為數位PCR和qPCR，RNA定序分為批量RNA定序和單細胞RNA定序。這些細分框架提供了一個全面的地圖，用於將研發藍圖、銷售策略和服務設計與不同客戶群的細微需求相結合。

區域情報觀點將美洲、歐洲、中東和非洲地區以及亞太地區的採用促進因素、監管變化和夥伴關係機會連結起來

區域動態在決定整個基因組學生態系統的採用模式、監管途徑和夥伴關係方面發揮著至關重要的作用。美洲擁有大型學術中心、綜合醫療保健系統和蓬勃發展的生物技術產業，這催生了對先進定序和精準診斷的需求，同時也促進了商業開發商和臨床實施者之間的密切合作。這種環境有利於將研究創新快速轉化為臨床檢驗試驗和商業部署。

歐洲、中東和非洲 (EMEA) 市場的特點是法律規範和醫療保健服務模式的多樣性，這對標準化和跨境合作產生了影響。該地區擁有強大的專業研究和轉化舉措能力，為利用專業知識和共用基礎設施的聯盟計劃提供了獨特的機會。合規性和國家報銷政策通常決定臨床應用的速度和軌跡。

在國內製造業投資、不斷成長的臨床定序項目以及日益增多的診斷實驗室的推動下，亞太地區在學術研究和商業應用領域的應用正在快速發展。公共衛生計劃和農業基因組學計畫等區域市場動態正在拓展基因組學技術的潛在應用。不同地區在報銷、監管透明度和製造能力方面的差異持續影響策略進入方式和夥伴關係模式。

以平台整合、服務擴展和策略夥伴關係關係為中心的供應商策略如何重新定義競爭優勢和客戶維繫

主要企業在平台整合、服務多元化和策略夥伴關係方面的投資正在塑造其競爭軌跡，從而獲取超越單一產品銷售的價值。將儀器創新與強大的試劑組合和擴充性服務相結合的公司，能夠提供滿足端到端客戶需求的整合解決方案。此外，在軟體、數據分析和雲端解讀服務方面的投資正在創造新的收益來源，並透過持續的服務模式增強客戶留存率。

對於尋求快速拓展潛在市場且避免重複資本投入的公司而言，策略聯盟和OEM合作關係日益普遍。此類聯盟可以加速新型檢測方法的上市時間，共用臨床檢驗風險，並提供互補的能力，進而提升整體解決方案的價值。同時，中端市場公司和專業創新者繼續提供差異化技術，尤其是在單細胞分析和新型文庫製備化學等利基應用領域。

競爭定位也取決於供應鏈和品質系統的卓越運作。能夠展現透明生產實踐、強大品管和快速響應的技術支援的開發人員將贏得關鍵終端用戶的信任，例如臨床實驗室和藥品開發人員。最終，最成功的公司將是那些能夠平衡技術差異化、可證明的客戶成果和可擴展商業模式的公司。

高階主管可以採取切實有效的行動來增強供應鏈彈性，實現平台互通性，並提供以結果為導向的服務來推動採用

為了因應不斷變化的基因組學環境，產業領導者必須採取一系列切實可行的措施，重點關注供應鏈彈性、平台互通性和價值主導的客戶參與。首先，企業應優先考慮關鍵耗材的雙重採購和本地庫存策略，以減輕貿易政策波動和物流中斷的影響。與關鍵供應商簽訂多年期合約並投資於供應商可視性工具，將降低風險並提供營運可預測性。

其次，產品和服務策略應強調互通性和資料可攜性。設計易於與常用實驗室資訊系統和生物資訊流程整合的儀器和軟體，可以降低採用門檻，並增強商業性關係的黏性。同樣重要的是注重以結果為導向的服務。將分析能力與解讀報告以及臨床或農業見解相結合，可以在競爭激烈的市場中脫穎而出。

最後，領導者應投資於監管準備和透明的資料管治實踐。積極與監管機構合作，採用最佳實踐驗證通訊協定，並展示強大的資料管理能力，可以加速臨床應用並建立相關人員的信任。在策略夥伴關係、共同開發契約和地理擴張方面的互補性投資，可以使組織在滿足本地市場需求的同時，負責任地擴大規模。這些綜合行動使行業領導者能夠在短期市場波動的情況下獲得長期價值。

採用嚴格的多源調查方法，結合主要相關人員訪談、專家文獻綜述和分析框架檢驗趨勢和策略意義

本研究採用了多層面的方法，結合了主要相關人員訪談、技術文獻綜述以及系統性的產品和研發分析，以確保觀點的全面性和平衡性。主要研究包括與研發負責人、臨床實驗室主任、採購專家以及儀器和試劑供應商的商業負責人的對話。這些對話旨在深入了解營運挑戰、應用促進因素以及對不斷變化的政策和供應鏈格局的策略反應。

我們的二次研究包括查閱同行評審日誌、會議論文集、專利申請和公開監管文件，以檢驗技術趨勢並追蹤關鍵技術的演變。此外，我們還整合了產品規格目錄、供應商揭露和公開案例研究，以繪製功能差距、整合能力和部署環境。調查方法著重於跨資訊來源三角測量，以減少偏見並協調對技術成熟度和臨床準備度的不同觀點。

此分析架構涵蓋細分市場映射、供應鏈風險情境規劃，以及基於定價、服務範圍和客戶支援安排的商業模式評估。在整個過程中，我們運用品質保證流程來核實事實準確性，並確保結論得到多項獨立輸入的支援。最終形成了一項嚴謹的、基於證據的評估，旨在為策略規劃和營運決策提供參考。

結論性綜合評估強調適應性、技術整合和管治是不斷發展的基因組學生態系統持續成功的關鍵因素

總而言之，我們重申，基因組學正處於曲折點，技術能力、商業性創新和監管管理在此交匯，決定未來的贏家和落後者。能夠將投資整合到可互通平台、彈性供應鏈和成果主導服務中的組織，將創造持久的競爭優勢。此外，積極應對監管和數據管治問題，將加速實驗室進步轉化為臨床和商業性效益。

展望未來，將複雜資料流轉化為可操作決策（例如開發治療方法、部署診斷方法和改進農業）的能力，將使高績效組織脫穎而出。策略夥伴關係、靈活的經營模式以及對客戶成果的持續關注，將使公司能夠抓住新機遇，同時降低營運風險。關鍵訊息是，適應性、技術力和可靠性是快速變化的基因組學生態系統中的關鍵要素。

最後，本分析為領導者確定投資優先順序、制定產品藍圖和完善商業性方法提供了結構性基礎。透過專注於那些對採用和價值實現影響最大的槓桿，組織能夠應對不確定性，並在研究、臨床護理和更廣泛的基因組學應用領域產生永續的影響。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 快速採用奈米孔長讀定序進行臨床診斷中的全面結構變異分析
  • 將多組體學數據與人工智慧演算法結合，加速標靶藥物研發流程
  • 隨著全球大流行防範工作的進展，利用可攜式定序設備擴大即時病原體監測
  • 直接面對消費者的基因健康檢測的擴展及其相關的隱私和監管挑戰
  • 用於早期癌症檢測和精準腫瘤學決策的新興表觀遺傳生物標記組
  • 主要國際市場對 CRISPR 基因編輯療法的監管協調努力
  • 引進雲端原生基因組資料平台，簡化研究協作與資料共用
  • 利用單細胞多體學分析揭示複雜疾病中的細胞異質性

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 基因組學市場（依產品類型）

  • 微陣列
    • 基因表現陣列
    • SNP基因型鑒定陣列
  • PCR
    • 數位PCR
    • 定量PCR
  • 試劑和耗材
    • 酵素和預混液
    • 文庫製備試劑套件
    • 探針和引子
  • 定序服務
    • NGS服務
    • 桑格定序服務
  • 定序系統
    • NGS平台
    • 桑格定序儀

第9章 基因組學市場（按應用）

  • 農業
    • 動物基因體學
    • 作物基因組學
  • 診斷
    • 癌症基因體學
    • 基因檢測
    • 傳染病檢查
  • 藥物研發
    • 生物標記發現
    • 目標識別
  • 個人化醫療
    • 伴隨診斷
    • 精準治療

第 10 章 基因組學市場（按最終用戶分類）

  • 學術和政府機構
  • 商業研究機構
  • 醫院和診所
  • 製藥和生物技術公司

第 11 章：基因組學市場（按技術）

  • 陣列技術
    • 微陣列基因表現
    • SNP基因型鑒定陣列
  • DNA序列分析
    • 次世代定序
    • 桑格定序
  • PCR技術
    • 數位PCR
    • 定量PCR
  • RNA定序
    • 批量RNA定序
    • 單細胞RNA定序

第12章 基因組學市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 13 章：基因組學市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。按國家/地區分類的基因組學市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd
    • QIAGEN NV
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • PerkinElmer, Inc.
    • BGI Genomics Co., Ltd.
    • Bio-Rad Laboratories, Inc.
    • Pacific Biosciences of California, Inc.
Product Code: MRR-434CCDA04CD1

The Genomics Market is projected to grow by USD 112.26 billion at a CAGR of 10.03% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 52.22 billion
Estimated Year [2025] USD 57.15 billion
Forecast Year [2032] USD 112.26 billion
CAGR (%) 10.03%

A strategic orientation that frames current genomics trends, technology considerations, and critical decisions for research, clinical, and commercial stakeholders

The landscape of genomics continues to evolve rapidly as technological innovation, cross-sector collaboration, and shifting regulatory expectations reshape strategic priorities for research institutions, healthcare providers, and commercial enterprises. This introduction synthesizes the principal drivers that executives, R&D leaders, and procurement teams must consider when evaluating technology adoption, partnership opportunities, and capital allocation. It situates the topic within the broader context of translational science, supply chain resilience, and the intensifying demand for precision approaches across therapeutics and diagnostics.

Emerging sequencing platforms, refinements in PCR modalities, and innovations in microarray design are unlocking new experimental capabilities while simultaneously altering vendor competition and service models. At the same time, applications spanning agriculture to personalized medicine are increasing the number of endpoints and data types that organizations must manage. Consequently, decisions about technology investments and outsourcing relationships are informed not only by instrument performance and reagent quality, but also by integration with bioinformatic pipelines, scalability of sample throughput, and long-term consumables availability.

Against this backdrop, stakeholders must weigh near-term operational needs against longer-term strategic objectives. This report's opening section frames the critical questions: how to prioritize platform selection in the face of heterogeneous use cases, how to mitigate supply and regulatory risks, and how to translate incremental technical advantages into measurable clinical or commercial value. The objective is to orient readers to the levers that will most significantly influence outcomes across research, clinical, and commercial settings.

How converging technology breakthroughs, evolving commercial models, and rising regulatory expectations are reshaping competitive dynamics and operational priorities in genomics

The genomics landscape is being transformed by an interplay of technological maturation, shifting business models, and emergent policy dynamics, producing structural shifts that require recalibrated strategies. Advances in high-throughput sequencing and single-cell capabilities have reduced barriers to generating complex datasets, which in turn is catalyzing a transition from siloed experiments to integrative multi-omic programs. This shift favors organizations that can combine analytical depth with robust data management and interpretation frameworks, thereby creating differentiation through actionable insights rather than raw throughput alone.

Concurrently, the commoditization of certain hardware components and the rise of reagent-focused business models are altering vendor economics and accelerating consolidation in segments where scale matters most. Service providers are expanding offerings to include end-to-end solutions that encompass sample logistics, sequencing, data processing, and regulatory support, thereby appealing to customers seeking simplicity and guaranteed quality. Meanwhile, increased interest in precision agriculture and infectious disease surveillance has broadened the range of end users and created adjacent markets where genomics capabilities can be deployed rapidly.

Finally, ethical and regulatory attention to data privacy, cross-border sample movement, and clinical validation is elevating governance as a competitive dimension. Organizations that proactively integrate compliance, transparent data stewardship, and validated workflows will be better positioned to capture long-term value. These transformative shifts are not isolated; they interact dynamically, meaning that technology choices, commercial partnerships, and compliance strategies must be aligned to navigate the new landscape effectively.

Assessment of how 2025 tariff measures have reshaped procurement strategies, supply chain resilience planning, and vendor risk allocation within genomics operations

The implementation of measures such as tariffs and trade restrictions can generate multi-layered effects on the genomics ecosystem, influencing supplier relationships, sourcing decisions, and cost structures for laboratory operations. Tariffs introduced in 2025 have had the effect of prompting procurement teams to reassess vendor portfolios, diversify sourcing, and accelerate qualification of alternative suppliers to ensure continuity of supply for critical instruments and consumables. This reorientation has placed a premium on suppliers with resilient manufacturing footprints and transparent tariff mitigation strategies.

In practice, organizations have responded by shifting some procurement toward domestically manufactured components or by increasing strategic inventory levels for high-use reagents and consumables. Contractual terms with service providers and instrument vendors have been renegotiated to account for extended lead times and to allocate risk related to cross-border logistics. Additionally, tariff-driven cost pressures have influenced capital expenditure planning, with some purchasers delaying non-essential instrument upgrades while prioritizing consumable availability for ongoing research and clinical workflows.

From a strategic perspective, the tariffs have underscored the importance of supply chain intelligence and scenario planning. Stakeholders are investing in deeper supplier audits, dual-sourcing strategies, and closer collaboration with manufacturers to map production capacity and identify chokepoints. In the medium term, these adaptations could encourage localized manufacturing expansion and longer-term contractual arrangements that provide visibility and predictability despite trade policy volatility. Thus, while tariffs create immediate challenges, they also accelerate structural changes in procurement practices and supply chain design across the genomics sector.

Comprehensive segmentation analysis that maps product, application, end-user, and technology dimensions to guide targeted R&D, commercialization, and service strategies

Understanding market segments is essential to shaping product development, commercial strategy, and service delivery models across the genomics domain. When the market is examined by product type, the analysis spans microarrays, PCR, reagents and consumables, sequencing services, and sequencing systems; the microarrays category further differentiates into gene expression arrays and SNP genotyping arrays, while PCR divides into digital PCR and qPCR; reagents and consumables encompass enzymes and master mixes, library preparation kits, and probes and primers; sequencing services include next-generation sequencing services and Sanger sequencing services; and sequencing systems distinguish between NGS platforms and Sanger sequencers. This product-centric view highlights where innovation is occurring and where lifecycle pressures on legacy platforms may prompt reinvestment or migration.

From an application perspective, the market covers agriculture, diagnostics, drug discovery and development, and personalized medicine. Within agriculture, the focus splits into animal genomics and crop genomics, reflecting differing sample types and analytical requirements. Diagnostics breaks down into cancer genomics, genetic testing, and infectious disease testing, each demanding distinct validation pathways and clinical workflows. Drug discovery and development emphasizes biomarker discovery and target identification, activities that rely on high-throughput, reproducible output. Personalized medicine includes companion diagnostics and precision therapeutics, areas where clinical integration and regulatory alignment are paramount.

Considering end users reveals a spectrum of organizational needs and purchasing behaviors, from academic and government institutes to commercial research organizations, hospitals and clinics, and pharmaceutical and biotechnology companies. These end users vary in procurement sophistication, throughput demands, and tolerance for operational risk. Evaluating the market through the lens of technology highlights the influence of array technology, DNA sequencing, PCR technology, and RNA sequencing. Array technology further divides into microarray gene expression and SNP genotyping arrays; DNA sequencing separates into next-generation sequencing and Sanger sequencing; PCR technology differentiates between digital PCR and qPCR; and RNA sequencing distinguishes bulk RNA sequencing from single-cell RNA sequencing. Together, these segmentation frameworks provide a comprehensive map to align R&D roadmaps, sales strategies, and service design with the nuanced needs of diverse customer cohorts.

A regional intelligence perspective that connects adoption drivers, regulatory diversity, and partnership opportunities across the Americas, EMEA, and Asia-Pacific markets

Regional dynamics play a decisive role in determining adoption patterns, regulatory pathways, and partnership opportunities across the genomics ecosystem. In the Americas, a concentration of large academic centers, integrated healthcare systems, and an active biotechnology sector creates demand for advanced sequencing and precision diagnostics, while fostering close collaboration between commercial developers and clinical implementers. This environment encourages rapid translation of research innovations into clinical validation studies and commercial deployments.

In Europe, Middle East & Africa, the market is characterized by diversity in regulatory frameworks and healthcare delivery models, which in turn affects standardization and cross-border collaboration. The region exhibits strong capabilities in specialized research and translational initiatives, and offers unique opportunities for consortium-based projects that leverage pooled expertise and shared infrastructure. Compliance considerations and national-level reimbursement policies often shape the pace and pathway for clinical adoption.

The Asia-Pacific region demonstrates fast-paced adoption in both academic research and commercial applications, driven by investments in domestic manufacturing, growing clinical sequencing programs, and a rising base of diagnostic laboratories. Local market dynamics, including public health initiatives and agricultural genomics programs, are expanding the addressable applications for genomic technologies. Across regions, variability in reimbursement, regulatory clarity, and manufacturing capacity will continue to influence strategic entry approaches and partnership models, making regional intelligence a critical input for global planning and local execution.

How vendor strategies centered on platform integration, service expansion, and strategic partnerships are redefining competitive advantage and customer retention

Company-level behavior is shaping competitive trajectories, with leading organizations investing in platform integration, service diversification, and strategic partnerships to capture value beyond single-product sales. Firms that combine instrument innovation with robust reagent portfolios and scalable service offerings are better positioned to deliver integrated solutions that meet end-to-end customer needs. Moreover, investments in software, data analytics, and cloud-enabled interpretive services are creating new revenue streams and strengthening customer lock-in through recurring service models.

Strategic alliances and OEM relationships are increasingly common as companies seek to expand addressable markets quickly without duplicating capital expenditures. These collaborations can accelerate time to market for novel assays, enable shared risk for clinical validation, and provide complementary capabilities that enhance total solution value. Meanwhile, mid-sized players and specialized innovators continue to contribute differentiated technologies, particularly in niche applications such as single-cell analytics or novel library preparation chemistries.

Competitive positioning also hinges on operational excellence in supply chain and quality systems. Companies that demonstrate transparent manufacturing practices, robust quality management, and responsive technical support capture trust among high-stakes end users such as clinical laboratories and pharmaceutical developers. Ultimately, the most successful companies will be those that balance technological differentiation with demonstrable customer outcomes and scalable commercial models.

Practical, high-impact actions for executives to enhance supply chain resilience, enable platform interoperability, and deliver outcome-focused services that drive adoption

Industry leaders must adopt a set of actionable responses to navigate the evolving genomics environment, focusing on supply chain resilience, platform interoperability, and value-driven customer engagement. First, organizations should prioritize dual-sourcing and localized inventory strategies for critical consumables to mitigate the effects of trade policy volatility and logistics disruptions. Establishing multi-year agreements with key suppliers and investing in supplier visibility tools will reduce risk and provide operational predictability.

Second, product and services strategies should emphasize interoperability and data portability. Designing instruments and software that facilitate integration with common laboratory information systems and bioinformatics pipelines will lower barriers to adoption and increase the stickiness of commercial relationships. Equally important is an emphasis on outcome-oriented services-packaging analytical capabilities with interpretive reporting and clinical or agronomic insights will differentiate offerings in a crowded marketplace.

Finally, leaders should invest in regulatory readiness and transparent data governance practices. Proactively engaging with regulatory authorities, adopting best-practice validation protocols, and demonstrating strong data stewardship will accelerate clinical adoption and build stakeholder trust. Complementary investments in strategic partnerships, co-development agreements, and targeted regional expansion will ensure that organizations can scale responsibly while responding to localized market needs. These actions, taken together, will position industry leaders to capture long-term value despite short-term market turbulence.

A rigorous, multi-source research methodology combining primary stakeholder interviews, technical literature review, and analytical frameworks to validate trends and strategic implications

This research employed a multi-faceted methodology that combined primary stakeholder interviews, technical literature review, and systematic analysis of product and regulatory developments to ensure a comprehensive and balanced perspective. Primary engagements included conversations with R&D leaders, clinical laboratory directors, procurement specialists, and commercial leaders across instrument and reagent providers. These interactions were structured to elicit insights into operational challenges, adoption drivers, and strategic responses to evolving policy and supply chain conditions.

Secondary research involved the review of peer-reviewed journals, conference proceedings, patent filings, and public regulatory documents to validate technical trends and to trace the evolution of key technologies. Additionally, catalogues of product specifications, vendor disclosures, and publicly available case studies were synthesized to map feature differentials, integration capabilities, and deployment contexts. The methodology emphasized triangulation across sources to reduce bias and to reconcile differing perspectives on technology maturity and clinical readiness.

Analytical frameworks included segmentation mapping, scenario planning for supply chain risk, and evaluation of commercial models based on pricing, service scope, and customer support structures. Throughout, quality assurance processes were applied to check factual accuracy and to ensure that conclusions are supported by multiple independent inputs. The result is a rigorous evidence-based assessment designed to inform strategic planning and operational decision-making.

A conclusive synthesis emphasizing adaptability, technical integration, and governance as the decisive factors for sustained success in the evolving genomics ecosystem

The concluding synthesis reiterates that genomics is at an inflection point where technological capability, commercial innovation, and regulatory stewardship intersect to define future winners and laggards. Organizations that align investments in interoperable platforms, resilient supply chains, and outcome-driven services will create durable competitive advantages. Moreover, proactive engagement with regulatory and data governance issues will accelerate the translation of laboratory advances into clinical and commercial impact.

Looking ahead, the ability to translate complex data streams into actionable decisions-whether for therapeutic development, diagnostic deployment, or agricultural improvement-will distinguish high-performing organizations. Strategic partnerships, flexible business models, and a relentless focus on customer outcomes will enable firms to capture emerging opportunities while mitigating operational risks. The key message is that adaptability, technical excellence, and trustworthiness are the principal currencies in a rapidly changing genomics ecosystem.

In closing, this analysis provides a structured foundation for leaders to prioritize investments, shape product roadmaps, and refine commercial approaches. By focusing on the levers that most strongly influence adoption and value realization, organizations can navigate uncertainty and position themselves for sustainable impact in research, clinical care, and broader applied genomics contexts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of nanopore long-read sequencing for comprehensive structural variant analysis in clinical diagnostics
  • 5.2. Integration of multi-omics data with AI algorithms to accelerate targeted drug discovery pipelines
  • 5.3. Scaling real-time pathogen surveillance through portable sequencing devices in global pandemic preparedness
  • 5.4. Expansion of direct-to-consumer genetic health testing and associated privacy and regulatory challenges
  • 5.5. Emergence of epigenetic biomarker panels for early cancer detection and precision oncology decision making
  • 5.6. Regulatory harmonization efforts for CRISPR gene editing therapies across major international markets
  • 5.7. Deployment of cloud-native genomic data platforms to streamline collaborative research and data sharing
  • 5.8. Utilization of single-cell multi-omics profiling to uncover cellular heterogeneity in complex diseases

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genomics Market, by Product Type

  • 8.1. Microarrays
    • 8.1.1. Gene Expression Arrays
    • 8.1.2. SNP Genotyping Arrays
  • 8.2. PCR
    • 8.2.1. Digital PCR
    • 8.2.2. qPCR
  • 8.3. Reagents & Consumables
    • 8.3.1. Enzymes & Master Mixes
    • 8.3.2. Library Preparation Kits
    • 8.3.3. Probes & Primers
  • 8.4. Sequencing Services
    • 8.4.1. NGS Services
    • 8.4.2. Sanger Sequencing Services
  • 8.5. Sequencing Systems
    • 8.5.1. NGS Platforms
    • 8.5.2. Sanger Sequencers

9. Genomics Market, by Application

  • 9.1. Agriculture
    • 9.1.1. Animal Genomics
    • 9.1.2. Crop Genomics
  • 9.2. Diagnostics
    • 9.2.1. Cancer Genomics
    • 9.2.2. Genetic Testing
    • 9.2.3. Infectious Disease Testing
  • 9.3. Drug Discovery & Development
    • 9.3.1. Biomarker Discovery
    • 9.3.2. Target Identification
  • 9.4. Personalized Medicine
    • 9.4.1. Companion Diagnostics
    • 9.4.2. Precision Therapeutics

10. Genomics Market, by End User

  • 10.1. Academic & Government Institutes
  • 10.2. Commercial Research Organizations
  • 10.3. Hospitals & Clinics
  • 10.4. Pharmaceutical & Biotechnology Companies

11. Genomics Market, by Technology

  • 11.1. Array Technology
    • 11.1.1. Microarray Gene Expression
    • 11.1.2. SNP Genotyping Arrays
  • 11.2. DNA Sequencing
    • 11.2.1. Next-Generation Sequencing
    • 11.2.2. Sanger Sequencing
  • 11.3. PCR Technology
    • 11.3.1. Digital PCR
    • 11.3.2. qPCR
  • 11.4. RNA Sequencing
    • 11.4.1. Bulk RNA Sequencing
    • 11.4.2. Single-Cell RNA Sequencing

12. Genomics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Genomics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Genomics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Illumina, Inc.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. F. Hoffmann-La Roche Ltd
    • 15.3.4. QIAGEN N.V.
    • 15.3.5. Danaher Corporation
    • 15.3.6. Agilent Technologies, Inc.
    • 15.3.7. PerkinElmer, Inc.
    • 15.3.8. BGI Genomics Co., Ltd.
    • 15.3.9. Bio-Rad Laboratories, Inc.
    • 15.3.10. Pacific Biosciences of California, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GENOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GENOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENOMICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GENOMICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENOMICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS GENOMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL GENOMICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL GENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GENOMICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. GENOMICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENOMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENOMICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GENOMICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENOMICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GENOMICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GENOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GENOMICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL GENOMICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL GENOMICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS GENOMICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS GENOMICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS GENOMICS MARKET SIZE, BY MICROARRAYS, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS GENOMICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS GENOMICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 321. AMERICAS GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 322. AMERICAS GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2025-2032 (USD MILLION)
  • TABLE 323. AMERICAS GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 324. AMERICAS GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 325. AMERICAS GENOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 326. AMERICAS GENOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 327. AMERICAS GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 328. AMERICAS GENOMICS MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 329. AMERICAS GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 330. AMERICAS GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 331. AMERICAS GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 332. AMERICAS GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 333. AMERICAS GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 334. AMERICAS GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 335. AMERICAS GENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. AMERICAS GENOMICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. AMERICAS GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 338. AMERICAS GENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 339. AMERICAS GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 340. AMERICAS GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 341. AMERICAS GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 342. AMERICAS GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 343. AMERICAS GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 344. AMERICAS GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 345. AMERICAS GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 346. AMERICAS GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2025-2032 (USD MILLION)

TABLE 347